Back to search

Article

Baseline expression levels of drug metabolizing enzymes in non-small cell lung cancer biopsies show promising biomarker and target potential for long-term response to pembrolizumab

2025-11-13

Abstract excerpt

Long-term responders (LTRs) to immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (NSCLC) are rare. As no robust biomarkers for LTRs have been defined so far, oncologists are unable to define the optimal treatment duration for this cohort. Hence, standard practice of ICI administration for at least 2 years, regardless of response, does not rely on a solid biological rationale. In this...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
56d454cd-800e-5026-a3b2-1b7de094f977
DOI
10.1101/2025.11.10.25339842
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Baseline expression levels of drug metabolizing enzymes in non-small cell lung cancer biopsies show promising biomarker and target potential for long-term response to pembrolizumabDOI 10.1101/2025.11.10.25339842
Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung CancerSemantic proximity
Complete remission after pembrolizumab monotherapy in a non-small cell lung cancer patient with PD-L1 negative, high tumor mutational burden, and positive tumor-infiltrating lymphocytes: A case report.Semantic proximity
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.Semantic proximity
Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancerSemantic proximity
Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression.Semantic proximity
Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.Semantic proximity
Blood Based Biomarkers for Predicting Treatment Response to Immune Checkpoint Inhibitors After EGFR-TKI Resistance in Non-Small Cell Lung Cancer.Semantic proximity
High Lymphocyte Population-related Predictive Factors for a Long-term Response in Non-small Cell Lung Cancer Patients Treated with Pemetrexed: A Retrospective Observational StudySemantic proximity
Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.Semantic proximity
Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung CancerSemantic proximity
Effects of the Hypomethylating Agent Guadecitabine on Peripheral Blood Mononuclear Cell Methylomes and Immune Cell Populations in Small-Cell Lung Cancer PatientsSemantic proximity
Select a neighboring publication to make it the new centre.